← Eichor
Condition: Prostatic Cancer Castration Resistant Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Prostatic Cancer Castration Resistant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT06828263Intestinal Akkermansia Muciniphila in Prostate Cancer
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06242509Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT05919329PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Phase 2 · 17 location(s) · VA Office of Research and Development · NCT05011383ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Phase N/A · 2 location(s) · Santa Chiara Hospital · NCT06783127ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Pros
Phase 2 · 15 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT07717268177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT05603559Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06200103A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re
Phase 1/Phase 2 · 82 location(s) · Merck Sharp & Dohme LLC · NCT06863272A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (
Phase 1 · 19 location(s) · Daiichi Sankyo · NCT07244341A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Met
Phase 2 · 1 location(s) · baotai Liang · NCT07250542Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06084338A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · 329 location(s) · Merck Sharp & Dohme LLC · NCT06136650Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 10 location(s) · Flare Therapeutics Inc. · NCT07719361Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 · 50 location(s) · Astellas Pharma Global Development, Inc. · NCT07005154Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.